Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 56, Issue 3, 2003, Pages 439-443

  Shin, Sang Chul ^a   Choi, Jun Shik ^b  

^a Chonnam National University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Atenolol; Bioavailability; Enhancer; Ethylene vinyl acetate matrix; Pharmacokinetics; Transdermal administration

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CITRIC ACID TRIBUTYL ESTER; ETHYLENE VINYL ACETATE COPOLYMER; POLYOXYETHYLENE OLEYL ETHER;

ABDOMEN; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; FEMORAL ARTERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; MALE; MEAN RESIDENCE TIME; NONHUMAN; RABBIT;

EID: 0242383495     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(03)00133-4     Document Type: Article

References (15)

1. Barrett A.M., Carter J., Fitzgerald J.D., Hull R., Count D. A new type of cardioselective adrenoceptive blocking drug. Br. J. Pharmacol. 48:1973;340.
2. Harry J.D., Knapp M.F., Linden R.J. Proceedings: antagonism by ICI 66082 of the effects of electrical stimulation on the right ansa subclavia of the dog. Br. J. Pharmacol. 51:1974;169.
3. Heel R.C., Brogden R.N., Speight T.M., Avery G.S. Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs. 17:1979;425-460.
4. Frishman W.H. Atenolol and timolol, two new systemic β- adrenoreceptor antagonists. N. Engl. J. Med. 306:1982;1424-1462.
5. Reeves P.R., Barnfield D.J., Longshaw S. Disposition and metabolism of atenolol in animals. Xenobiotica. 8:1978;305-311.
6. Brown H.C., Carruthers M.D., Johnston G.D. Clinical pharmacologic observations on atenolol, a β-adrenoreceptor blocker. Clin. Pharmacol. Ther. 20:1976;524-534.
7. Stoschitzky K., Egginger G., Zernig G., Klein W., Linder W. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic and radioligard binding studies. Chirality. 5:1993;15-19.
8. Fitzgerald J.D. The biological an clinical effects of atenolol (Tenormin), a cardioselective-antagonist. Goldberg M.E. Pharmacological and Biochemical Properties of Drug Substances. II:1979;American Pharmaceutical Association Press, Washington, DC.
9. Van Zwieten P.A., Timmermans P.B.M. Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol. J. Cardiovasc. Pharmacol. 1:1979;85.
10. Cruickshank J.M., Neil-Dwyer G., Cameron M.M., McAinsh J. Beta Blockers and the Central Nervous System (CNS) Abstract. 1979;6th Scientific Meeting of the International Society of Hypertension, Goteborg, Sweden.
11. Barber H.E., Hawksworth G.J., Kitteringham N.R. Protein binding of atenolol and propranolol to human serum albumin and in human plasma. Br. J. Clin. Pharmacol. 6:1978;446-447.
12. AHFS Drug information. 2002;AHFS, MD, USA.
13. Shin S.C., Kim J., Park Y.S., Pack M.K., Oh L.J. Enhanced controlled release of atenolol from the EVA matrix. 2003;Proceedings: 2003 Annual Meeting of the Controlled Release Society, Glasgow, United Kingdom.
14. Rocci M.L., Jusko W.J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:1983;203-216.
15. Winkler H., Ried W., Lemmer B. High-performance liquid chromatoratographic method of the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue. J. Chromatogr. 228:1982;223-224.